Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation

Balassa, Katalin; Salisbury, Richard; Watson, Edmund; Lubowiecki, Marcin; Tseu, Bing; Maouche, Nadjoua; Jeffery, Katie; Misbah, Siraj; Benamore, Rachel; Rowley, L; Barton, Daja; Pawson, Rachel; Danby, Robert; Rocha, Vanderson; Peniket, Andy

doi:10.1016/j.jinf.2019.04.004

Cited by 10 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study showed that hypogammaglobulinemia was a significant risk factor for fatal outcomes of RSV infections in a hematology and transplant unit, and treatment with IVIg at regular doses was unable to reverse the poor prognosis (230). By contrast, oral RBV in combination with high-dose IVIg therapy (rather than lower doses), have been potentially attributed to the improvement of survival in RSV-infected allogeneic hematopoietic stem cell transplanted (HSCT) patients (231). The dosage of IVIg might be the critical factor for efficacy of therapy, since the combination of high-dose IVIg and aerosolized RBV therapy has also been shown to be a safe and promising approach to prevent progression of RSV infections immunocompromised patients (232).…”

Section: Ivig In Treating Rsv Infectionmentioning

confidence: 99%

High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects

Liu

Cao

2020

Front. Immunol.

View full text Add to dashboard Cite

The current outbreak of viral pneumonia, caused by novel coronavirus SARS-CoV-2, is the focus of worldwide attention. The WHO declared the COVID-19 outbreak a pandemic event on Mar 12, 2020, and the number of confirmed cases is still on the rise worldwide. While most infected individuals only experience mild symptoms or may even be asymptomatic, some patients rapidly progress to severe acute respiratory failure with substantial mortality, making it imperative to develop an efficient treatment for severe SARS-CoV-2 pneumonia alongside supportive care. So far, the optimal treatment strategy for severe COVID-19 remains unknown. Intravenous immunoglobulin (IVIg) is a blood product pooled from healthy donors with high concentrations of immunoglobulin G (IgG) and has been used in patients with autoimmune and inflammatory diseases for more than 30 years. In this review, we aim to highlight the known mechanisms of immunomodulatory effects of high-dose IVIg therapy, the immunopathological hypothesis of viral pneumonia, and the clinical evidence of IVIg therapy in viral pneumonia. We then make cautious therapeutic inferences about high-dose IVIg therapy in treating severe COVID-19. These inferences may provide relevant and useful insights in order to aid treatment for COVID-19.

show abstract

Section: Ivig In Treating Rsv Infectionmentioning

confidence: 99%

High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects

Liu

Cao

2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…45,48 The most commonly reported epidemiological outcome was incidence of RSV infection, reported by 24 studies in total, F followed by mortality, reported by five studies. 14,35,41,45,57 (Table S13). 14,36,[42][43][44][46][47][48][49][51][52][53][54][55][56]59,60 Epidemiological outcomes were reported by 15 studies; 14 reported on RSV infection incidence, 36,[42][43][44][46][47][48][49][51][52][53][54][55][56] and 1 study reported mortality.…”

Section: Search Resultsmentioning

confidence: 99%

“…Two other studies compared the incidence of upper and lower respiratory tract infections (URTIs and LRTIs) in RSV patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). Balassa et al 35 reported a slightly higher rate of drug usage and two reported inpatient stays, finding moderate resource use. 35,41,45 Five studies reported on a co-infected patient population and presented the annual incidence of RSV in patients with invasive pneumococcal disease, leptospirosis, COVID-19 and community-acquired pneumonia.…”

Section: Burden Of Rsv In Other High-risk Patient Groupsmentioning

confidence: 94%

“…Balassa et al 35 reported a slightly higher rate of drug usage and two reported inpatient stays, finding moderate resource use. 35,41,45 Five studies reported on a co-infected patient population and presented the annual incidence of RSV in patients with invasive pneumococcal disease, leptospirosis, COVID-19 and community-acquired pneumonia. 38,40,50,57,58 Incidence rates across these studies ranged from 0% (15-44 years, invasive pneumococcal disease; laboratory and database setting 38…”

Section: Burden Of Rsv In Other High-risk Patient Groupsmentioning

confidence: 94%

See 1 more Smart Citation

Burden of respiratory syncytial virus in adults in the United Kingdom: A systematic literature review and gap analysis

Wilkinson,

Beaver,

Macartney

et al. 2023

Influenza Resp Viruses

View full text Add to dashboard Cite

Despite the growing recognition of a potentially significant respiratory syncytial virus (RSV) disease burden in adults, relevant evidence in the United Kingdom (UK) is limited. This systematic literature review (SLR) aimed to identify the disease burden of RSV in UK adults, including certain high‐risk subgroups and existing evidence gaps. Published studies (2011 onwards) reporting epidemiological, economic and clinical burden outcomes in UK adults (≥15 years) with RSV were identified from indexed databases, including MEDLINE, Embase and the Cochrane library. High‐risk groups included elderly (≥65 years), immunocompromised, co‐morbid and co‐infected patients. Outcomes included RSV incidence/prevalence, mortality, clinical presentation and direct/indirect resource use/costs. Twenty‐eight publications on 28 unique studies were identified, mostly in general/respiratory indicator (n = 17), elderly (n = 10) and immunocompromised (n = 6) cohorts. Main outcomes reported in the general/respiratory indicator cohort were RSV infection incidence (seasonal/annual: 0.09–17.9%/6.6–15.1%), mortality (8,482 deaths/season) and direct resource use (including mean general practitioner [GP] episodes/season: 487,247). Seasonal/annual incidence was 14.6–26.5%/0.7–16% in high‐risk cohorts. Attributed to RSV in the elderly were 7,915 deaths/season and 175,070 mean GP episodes/season. Only two studies reported on co‐morbid cohorts. Clinical burden outcomes were only reported in general and immunocompromised patients, and no evidence was found in any cohort on indirect economic burden or RSV complications. Evidence captured suggests that RSV may have a substantial burden in UK adults. However, available data were limited and highly heterogenous, with further studies needed to characterise the burden of RSV in adults and to validate our findings.

show abstract

“…O isolamento de casos suspeitos com sintomatologia respiratória, em ambiente hospitalar, até melhora completa dos sintomas, assim como os cuidados com a higiene pessoal é conduta essencial no TCTH. A evolução da infecção do trato respiratório superior para o inferior, que pode acontecer em situações de infecção pelo RSV (13) , por exemplo, também precisa ser monitorada pelo enfermeiro, por meio da avaliação da condição clínica da criança.…”

Section: Discussionunclassified

Construção de protocolo de cuidados de enfermagem à criança no pós-transplante de células-tronco hematopoiéticas

Rodrigues

Lacerda

Galvão

et al. 2022

Rev. Gaúcha Enferm.

View full text Add to dashboard Cite

RESUMO Objetivo: Construir protocolo de cuidados de enfermagem à criança no pós-transplante de células-tronco hematopoiéticas. Método: Pesquisa metodológica conduzida entre janeiro e setembro de 2019 e, em três etapas: a) realização de revisão integrativa (cuidados de enfermagem foram identificados); b) estruturação e organização teórica de cuidados a partir da Teoria das Necessidades Humanas Básicas e da Classificação Internacional para a Prática de Enfermagem, complementando os dados da revisão; c) desenvolvimento do protocolo, cuja elaboração integrou as etapas anteriores. A análise de compreensão de itens/cuidados do protocolo foi realizada por três enfermeiros especialistas. Resultados: O protocolo de cuidados é composto por 40 problemas de enfermagem e está organizado de acordo com as necessidades psicobiológicas, psicossociais e psicoespirituais de crianças submetidas ao transplante, integrando cuidados práticos e de orientação. Conclusão: O protocolo é opção tecnológica para a assistência de enfermagem à criança transplantada, com vistas à prevenção e manejo das complicações.

show abstract

Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation

Cited by 10 publications

References 35 publications

High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects

High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects

Burden of respiratory syncytial virus in adults in the United Kingdom: A systematic literature review and gap analysis

Construção de protocolo de cuidados de enfermagem à criança no pós-transplante de células-tronco hematopoiéticas

Contact Info

Product

Resources

About